Mylan Debt to Equity Ratio 2006-2018 | MYL

Current and historical debt to equity ratio values for Mylan (MYL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Mylan debt/equity for the three months ending September 30, 2018 was 1.20.
Mylan Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $14.44B $12.07B 1.20
2018-06-30 $14.38B $12.21B 1.18
2018-03-31 $13.58B $13.18B 1.03
2017-12-31 $14.10B $13.31B 1.06
2017-09-30 $13.99B $13.29B 1.05
2017-06-30 $15.39B $12.83B 1.20
2017-03-31 $16.07B $11.66B 1.38
2016-12-31 $16.56B $11.12B 1.49
2016-09-30 $12.97B $11.83B 1.10
2016-06-30 $12.77B $10.33B 1.24
2016-03-31 $7.67B $10.28B 0.75
2015-12-31 $6.30B $9.77B 0.65
2015-09-30 $7.20B $9.82B 0.73
2015-06-30 $7.27B $9.57B 0.76
2015-03-31 $7.13B $9.09B 0.78
2014-12-31 $7.04B $3.28B 2.15
2014-09-30 $7.00B $3.41B 2.05
2014-06-30 $9.22B $3.35B 2.75
2014-03-31 $9.05B $3.19B 2.83
2013-12-31 $8.86B $2.96B 2.99
2013-09-30 $6.81B $3.23B 2.11
2013-06-30 $6.66B $2.95B 2.26
2013-03-31 $6.45B $2.89B 2.23
2012-12-31 $6.11B $3.36B 1.82
2012-09-30 $5.21B $3.62B 1.44
2012-06-30 $5.55B $3.20B 1.74
2012-03-31 $5.29B $3.78B 1.40
2011-12-31 $5.22B $3.51B 1.49
2011-09-30 $4.82B $3.49B 1.38
2011-06-30 $5.18B $3.88B 1.34
2011-03-31 $5.12B $3.92B 1.31
2010-12-31 $5.63B $3.62B 1.56
2010-09-30 $5.67B $3.54B 1.60
2010-06-30 $5.51B $2.98B 1.85
2010-03-31 $5.54B $3.18B 1.74
2009-12-31 $5.47B $3.14B 1.74
2009-09-30 $5.53B $3.07B 1.80
2009-06-30 $5.39B $2.91B 1.85
2009-03-31 $5.37B $2.65B 2.03
2008-12-31 $5.50B $2.79B 1.98
2008-09-30 $5.46B $2.98B 1.83
2008-06-30 $4.95B $3.13B 1.58
2008-03-31 $4.97B $3.16B 1.58
2007-12-31 $4.91B $3.40B 1.44
2007-09-30 $1.61B $1.89B 0.85
2007-06-30 $1.70B $1.73B 0.98
2007-03-31 $1.69B $1.65B 1.02
2006-12-31 $0.71B $1.10B 0.64
2006-09-30 $0.71B $0.96B 0.74
2006-06-30 $0.71B $0.87B 0.82
2006-03-31 $0.71B $0.79B 0.90
2005-12-31 $0.79B $0.76B 1.04
2005-09-30 $0.79B $0.83B 0.95
2005-06-30 $0.02B $1.88B 0.01
2005-03-31 $0.02B $1.85B 0.01
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $17.650B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $53.197B 9.13
Teva Pharmaceutical Industries (TEVA) Israel $23.053B 7.06
Bausch Health Cos (BHC) Canada $9.251B 6.70
Dr Reddy's Laboratories (RDY) India $5.675B 22.66
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.575B 4.29
Supernus Pharmaceuticals (SUPN) United States $2.250B 21.32
Amphastar Pharmaceuticals (AMPH) United States $0.928B 100.65
Akorn (AKRX) United States $0.846B 0.00
Homology Medicines (FIXX) United States $0.747B 0.00
Assembly Biosciences (ASMB) United States $0.569B 0.00
CymaBay Therapeutics (CBAY) United States $0.542B 0.00
Corium (CORI) United States $0.458B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.429B 0.00
Voyager Therapeutics (VYGR) United States $0.366B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.297B 0.00
Teligent (TLGT) United States $0.153B 0.00
Sol-Gel Technologies (SLGL) Israel $0.129B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.091B 0.00
Aevi Genomic Medicine (GNMX) United States $0.073B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.051B 0.00
Evoke Pharma (EVOK) United States $0.046B 0.00
Acasti Pharma (ACST) Canada $0.037B 0.00
Agile Therapeutics (AGRX) United States $0.030B 0.00
China Pharma Holdings (CPHI) China $0.016B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00